Navigation Links
HeartWare International Reports Fourth Quarter 2012 Revenue Of $32.7 Million; Full Year 2012 Revenue Of $110.9 Million
Date:2/27/2013

by 6 percent compared to the same period in 2011. 

"With 345 HVAD® pumps sold during the fourth quarter, the largest number in any quarter to date, the total number of pumps sold in 2012 was 1,217, compared to 932 pumps sold in 2011," added Mr. Godshall. "Our team has been working diligently to expedite the training of additional hospitals in the U.S., and since FDA approval 18 new U.S. sites have been trained, with 2 more in training this week."

Total operating expenses for the fourth quarter of 2012 were $35.4 million, as compared to $30.8 million in the same period of 2011. 

Research and development expense was $22.2 million for the fourth quarter of 2012, as compared to $17.9 million in the same period of 2011.  Increased development costs are a result of continuing clinical trial costs and research and development costs related to advancing HeartWare's pipeline technologies, including the MVAD® platform and a fully implantable system, as well as other early research initiatives.

Selling, general and administrative expenses were $13.3 million in the fourth quarter of 2012, compared to $12.9 million in the fourth quarter of 2011.  The increase in selling, general and administrative expenses is related to continued growth supporting commercial activity outside of the U.S., preparation for and rollout of the commercial launch in the U.S., and an overall increase in corporate infrastructure to support the Company's rapid growth. 

Net loss for the fourth quarter of 2012 was $21.1 million, or a $1.46 loss per basic and diluted share, compared to a $21.6 million net loss, or a loss of $1.53 per basic and diluted share, in the fourth quarter of 2011.  For the fiscal year ended December 31, 2012, the Company recorded a net loss of $87.7 million, or a $6.15 loss per basic and diluted share, compared to a $55.1 million net loss, or a loss of $3.94 per basic and diluted shar
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. HeartWare Schedules Fourth Quarter Conference Call and Webcast
2. HeartWare Presentation at Leerink Swann Global Healthcare Conference to be Webcast
3. HeartWare Presentation at the Oppenheimer 23rd Annual Healthcare Conference to be Webcast
4. HeartWare Presentation At The 24th Annual Piper Jaffray Healthcare Conference To Be Webcast
5. HeartWare Presentation At The Lazard Capital Markets 9th Annual Healthcare Conference To Be Webcast
6. HeartWare Reports Third Quarter 2012 Results
7. HeartWare Schedules Third Quarter Conference Call And Webcast
8. HeartWare Presentation at the UBS Global Life Sciences Conference to be Webcast
9. HeartWare Presentation At The Canaccord Genuity 32nd Annual Growth Conference To Be Webcast
10. HeartWare Presentation at the 2012 Wedbush PacGrow Lifesciences Management Access Conference to be Webcast
11. HeartWare Reports Second Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)...   EVO Aesthetic Center and Wellness Spa ... aesthetics in Lakeway, Texas and ... Astanza Duality laser. The medical spa is focused on ... and laser procedures. Their addition of the Astanza Duality ... to their tattoo regret. "The large number ...
(Date:7/2/2015)... , July 2, 2015 Pharma Major ... in ZAO "Biocom" in Russia subject ... the Russian pharmaceutical market which recorded RUB 765 billion in ... markets in the world in 2014 (IMS Health). For over ... expected to continue with this trend, projecting Russia ...
(Date:7/2/2015)... 2015 The report "Silage Inoculants ... (Lactobacillus, Pediococcus & Enterococcus), Enzymes (Fibre-digesting & Starch-digesting), Crop-type ... Silage Inoculants & Enzymes Market is expected to reach ... from 2015 to 2020. Browse 75 ... 194 P ages and an in-depth ...
Breaking Medicine Technology:EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2Lupin Acquires Biocom in Russia 2Lupin Acquires Biocom in Russia 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 2Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 4
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ... solutions and management consulting services to the federal government, has announced they are ... Indefinite-Quantity (IDIQ), Business Management Office Support Services (BMOSS) contract not to exceed $250 ...
(Date:7/2/2015)... , ... July 02, 2015 , ... Hand sanitizers have ... current summer flu season, according to fresh water advocate and radio host Sharon Kleyne, ... hands. Kleyne cautions that for maximum effectiveness, hand sanitizers must be applied correctly and ...
(Date:7/2/2015)... Mountain Home, AR (PRWEB) , ... July 02, 2015 , ... ... to military families through their annual “Dog Tag” campaign. On Tuesday, July 7, ... For The Warriors® for nearly $800,000. Hope For The Warriors® is a national nonprofit ...
(Date:7/2/2015)... , ... July 02, 2015 , ... ... and development solutions for drugs, biologics and consumer health products, today announced that ... , Dr. Irmgard Neuper is the new General Manager at Catalent’s Schorndorf facility, ...
(Date:7/2/2015)... ... 02, 2015 , ... A team of quality control (QC) experts at GE ... QC laboratory for enhanced workflow. Now, Dr. Dunne’s lab has set a lofty goal: ... Healthcare Diagnostic Imaging network. , Join the team members for a new, free ...
Breaking Medicine News(10 mins):Health News:Octo Consulting Group Awarded IDIQ Contract for SEC Business Management Support 2Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 2Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 3Health News:Casey’s General Stores to Present Donation from “Dog Tag” Campaign to Hope For The Warriors® 2Health News:Casey’s General Stores to Present Donation from “Dog Tag” Campaign to Hope For The Warriors® 3Health News:Catalent Makes Two Key European Appointments in Oral Dose Manufacturing 2Health News:GE Healthcare Webinar Spotlights GE’s Own, Internal QC Lab Enhancements with Six Sigma 2Health News:GE Healthcare Webinar Spotlights GE’s Own, Internal QC Lab Enhancements with Six Sigma 3
... -- Low doses of a drug used to prevent ... considerably reduces hot flashes in patients undergoing anti-hormonal treatment, ... the result of a study carried out by North ... in Rochester, Minn. ,In presenting results of ...
... can feel a bit relaxed now. Genosis Inc, a US ... Fertell. The test has his and hers components ... device to measure the concentration of motile sperm, and a ... of egg quality. ,The availability of the two-in-one ...
... D.C. At the 54th Annual Meeting of SNM, ... nuclear medicine professionals, German researchers stated that ... accurately identifies patients responding to chemotherapy for esophageal ... to apply PET results from early metabolic response ...
... Organizations (AAPPO) is launching a new initiative to help ... patients diagnosed with diabetes as well as encourage ... AAPPO today kicked off its new ACT on Diabetes ... better care, and empower their patients to Take charge ...
... HIVmirror LLC, a Philadelphia-based company offering HIV positive ... announcing the launch of their innovative HIV progression ... its user-friendly Web site (http: www.hivmirror.com), empowers modern ... genetic code and its role in their potential ...
... ability to get in and see the doctor will be ... physicians, according to a new survey released today by ... national campaign to stop next year's 10 percent cut, was ... bleak picture for the future of Medicare. ,"The ...
Cached Medicine News:Health News:Hot Flashes in Men Treated for Prostate Cancer Reduced by Non-hormonal Drug 2Health News:Hot Flashes in Men Treated for Prostate Cancer Reduced by Non-hormonal Drug 3Health News:Fertility Test at Home Possible With a New Kit 2Health News:Esophageal Cancer Patients' Positive Responses to Chemotherapy Accurately Identified by PET 2Health News:AAPPO Launches ACT on Diabetes Initiative to Promote Improved Diabetes Care 2Health News:HIVmirror, LLC Launching Breakthrough Genetic Product for HIV Positive Consumer 2Health News:New AMA Survey Finds Medicare Cuts Will Hurt Seniors 2Health News:New AMA Survey Finds Medicare Cuts Will Hurt Seniors 3
... The quanTtest human protein standards are available ... 100 and 200 mg/dL and are packaged ... liquid, ready-to-use, requiring no reconstitution or dilution ... using purified human albumin and human globulin ...
... binding method provides a simple, ready-to-use ... with greater linearity, using microliter samples ... in manual or automated systems. Assay ... 2, 3, 4 & 5), reagents, ...
... This control is intended as a ... testing methods. A new feature is ... CRP. It is compatible with most ... ACS:180, Access, Dimension, Elecsys, Stratus and ...
The Clearblue Easy Ovulation Test detects the surge of "luteinizing hormone in your urine, which usually happens 24 to 36 hours before you ovulate (release an egg). That means youll know the 2 best ...
Medicine Products: